North America Minimal Residual Disease (MRD) Testing Market 2022-2031 by Offering (Services, Test Kits & Consumables), Application (NHL, MM, ALL, CLL, AML, CML, HL, Solid Tumor), Technology (Flow Cytometry, PCR, NGS, Others), End User (Hospitals and Clinics, Research Institutions, Diagnostic Laboratories, Others), and Country: Trend Forecast and Growth Opportunity
- Report ID: 43023
- Date: Aug, 2022
- Pages: 108
- Category: Healthcare & Pharmaceuticals
North America minimal residual disease (MRD) testing market is projected to grow by 11.1% annually in the forecast period and reach $ 1,056.1 million by 2031, driven by the rising prevalence of hematological malignancy and cancer, the aging population, technological advancements in diagnostics and therapies due to increasing R&D investment, and the growing healthcare expenditure.
Highlighted with 27 tables and 51 figures, this 108-page report “North America Minimal Residual Disease (MRD) Testing Market 2022-2031 by Offering (Services, Test Kits & Consumables), Application (NHL, MM, ALL, CLL, AML, CML, HL, Solid Tumor), Technology (Flow Cytometry, PCR, NGS, Others), End User (Hospitals and Clinics, Research Institutions, Diagnostic Laboratories, Others), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America minimal residual disease (MRD) testing market and all its sub-segments through extensively detailed classifications.
Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2022 and provides forecast from 2022 till 2031 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify North America minimal residual disease (MRD) testing market in every aspect of the classification from perspectives of Offering, Application, Technology, End User, and Country.
Based on Offering, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section.
• Services
• Test Kits & Consumables
Based on Application, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section.
• Non-Hodgkin's Lymphoma (NHL)
o DLBCL
o Marginal Zone Lymphoma
o Follicular Lymphoma
o Peripheral T-cell Lymphoma
o Mantle Cell Lymphoma
o Other NHLs
• Multiple Myeloma (MM)
• Acute Lymphoblastic Leukemia (ALL)
• Chronic Lymphoblastic Leukemia (CLL)
• Acute Myeloid Leukemia (AML)
• Chronic Myeloid Leukemia (CML)
• Hodgkin's Lymphoma (HL)
• Solid Tumor
• Other Applications
By Technology, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section.
• Flow Cytometry
• Polymerase Chain Reaction (PCR)
• Next-Generation Sequencing (NGS)
• Other Technologies
By End User, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section.
• Hospitals and Clinics
• Research Institutions
• Diagnostic Laboratories
• Other End Users
Geographically, the following national/local markets are fully investigated:
• U.S.
• Canada
• Mexico
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2022-2031. The breakdown of national markets by Application, Technology, and End User over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Adaptive Biotechnologies Corporation
ArcherDX, Inc. (Invitae Corporation)
Arup Laboratories
Asuragen Inc.
Bio-Rad Laboratories, Inc.
Cergentis B.V.
Guardant Health
ICON plc
Inivata Ltd.
Invivoscribe, Inc.
Laboratory Corporation of America Holdings
Mission Bio, Inc.
Natera, Inc.
NeoGenomics Laboratories, Inc.
Opko Health, Inc.
Quest Diagnostics Incorporated
Sysmex Corporation
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 Market Overview and Dynamics 19
2.1 Market Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 20
2.1.2 Impact of COVID-19 on the Market 22
2.2 Major Growth Drivers 24
2.3 Market Restraints and Challenges 30
2.4 Emerging Opportunities and Market Trends 33
2.5 Porter’s Fiver Forces Analysis 37
3 Segmentation of North America Market by Offering 41
3.1 Market Overview by Offering 41
3.2 Services 43
3.3 Test Kits & Consumables 44
4 Segmentation of North America Market by Application 45
4.1 Market Overview by Application 45
4.2 Non-Hodgkin’s Lymphoma (NHL) 47
4.2.1 DLBCL 49
4.2.2 Marginal Zone Lymphoma 50
4.2.3 Follicular Lymphoma 51
4.2.4 Peripheral T-cell Lymphoma 52
4.2.5 Mantle Cell Lymphoma 53
4.2.6 Other NHLs 54
4.3 Multiple Myeloma (MM) 55
4.4 Acute Lymphoblastic Leukemia (ALL) 56
4.5 Chronic Lymphoblastic Leukemia (CLL) 57
4.6 Acute Myeloid Leukemia (AML) 58
4.7 Chronic Myeloid Leukemia (CML) 59
4.8 Hodgkin’s Lymphoma (HL) 60
4.9 Solid Tumor 61
4.10 Other Applications 62
5 Segmentation of North America Market by Technology 63
5.1 Market Overview by Technology 63
5.2 Flow Cytometry 65
5.3 Polymerase Chain Reaction (PCR) 66
5.4 Next-Generation Sequencing (NGS) 67
5.5 Other Technologies 68
6 Segmentation of North America Market by End User 69
6.1 Market Overview by End User 69
6.2 Hospitals and Clinics 71
6.3 Research Institutions 72
6.4 Diagnostic Laboratories 73
6.5 Other End Users 74
7 North America Market 2021-2031 by Country 75
7.1 Overview of North America Market 75
7.2 U.S. 78
7.3 Canada 81
7.4 Mexico 83
8 Competitive Landscape 85
8.1 Overview of Key Vendors 85
8.2 New Product Launch, Partnership, Investment, and M&A 89
8.3 Company Profiles 90
Adaptive Biotechnologies Corporation 90
ArcherDX, Inc. (Invitae Corporation) 92
Arup Laboratories 93
Asuragen Inc. 94
Bio-Rad Laboratories, Inc. 95
Cergentis B.V. 96
Guardant Health 97
ICON plc 98
Inivata Ltd. 99
Invivoscribe, Inc. 100
Laboratory Corporation of America Holdings 101
Mission Bio, Inc. 102
Natera, Inc. 103
NeoGenomics Laboratories, Inc. 104
Opko Health, Inc. 105
Quest Diagnostics Incorporated 106
Sysmex Corporation 107
RELATED REPORTS 108
List of Tables
Table 1. Snapshot of North America Minimal Residual Disease Testing Market in Balanced Perspective, 2021-2031 17
Table 2. World Economic Outlook, 2021-2031 21
Table 3. World Health Spending by Region, $ bn, 2013-2020 29
Table 4. Main Product Trends and Market Opportunities in North America Minimal Residual Disease Testing Market 33
Table 5. North America Minimal Residual Disease Testing Market by Offering, 2021-2031, $ mn 41
Table 6. North America Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 45
Table 7. North America Minimal Residual Disease Testing Market: Non-Hodgkin’s Lymphoma (NHL) by Type, 2021-2031, $ mn 48
Table 8. North America Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 63
Table 9. Main Vendors and Products of Flow Cytometry Technology 65
Table 10. Main Vendors and Products of Polymerase Chain Reaction (PCR) Technology 66
Table 11. Main Vendors and Products of Next-Generation Sequencing (NGS) Technology 67
Table 12. North America Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 69
Table 13. North America Minimal Residual Disease Testing Market by Country, 2021-2031, $ mn 76
Table 14. U.S. Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 80
Table 15. U.S. Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 80
Table 16. U.S. Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 80
Table 17. Canada Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 82
Table 18. Canada Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 82
Table 19. Canada Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 82
Table 20. Mexico Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 84
Table 21. Mexico Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 84
Table 22. Mexico Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 84
Table 23. Breakdown of World Market by Key Vendor, 2021, % 87
Table 24. Approved and Launched MRD Testing Products of Key Vendors 87
Table 25. Adaptive Biotechnologies Corporation: Company Snapshot 90
Table 26. Adaptive Biotechnologies Corporation: Business Segmentation 91
Table 27. Adaptive Biotechnologies Corporation: Product Portfolio 91
List of Figures
Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031 16
Figure 4. North America Minimal Residual Disease Testing Market, 2021-2031, $ mn 19
Figure 5. Impact of COVID-19 on Business 22
Figure 6. Primary Drivers and Impact Factors of North America Minimal Residual Disease Testing Market 24
Figure 7. World Number of Deaths from Cancers in 201 27
Figure 8. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 28
Figure 9. World Population 65 and Over, % of Total Population, 1950-2060 28
Figure 10. Primary Restraints and Impact Factors of North America Minimal Residual Disease Testing Market 30
Figure 11. Investment Opportunity Analysis 34
Figure 12. Porter’s Fiver Forces Analysis of North America Minimal Residual Disease Testing Market 37
Figure 13. Breakdown of North America Minimal Residual Disease Testing Market by Offering, 2021-2031, % of Revenue 42
Figure 14. North America Addressable Market Cap in 2022-2031 by Offering, Value ($ mn) and Share (%) 42
Figure 15. North America Minimal Residual Disease Testing Market by Offering: Services, 2021-2031, $ mn 43
Figure 16. North America Minimal Residual Disease Testing Market by Offering: Test Kits & Consumables, 2021-2031, $ mn 44
Figure 17. Breakdown of North America Minimal Residual Disease Testing Market by Application, 2021-2031, % of Sales Revenue 46
Figure 18. North America Addressable Market Cap in 2022-2031 by Application, Value ($ mn) and Share (%) 46
Figure 19. North America Minimal Residual Disease Testing Market by Application: Non-Hodgkin’s Lymphoma (NHL), 2021-2031, $ mn 47
Figure 20. North America Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): DLBCL, 2021-2031, $ mn 49
Figure 21. North America Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Marginal Zone Lymphoma, 2021-2031, $ mn 50
Figure 22. North America Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Follicular Lymphoma, 2021-2031, $ mn 51
Figure 23. North America Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Peripheral T-cell Lymphoma, 2021-2031, $ mn 52
Figure 24. North America Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Mantle Cell Lymphoma, 2021-2031, $ mn 53
Figure 25. North America Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Other NHLs, 2021-2031, $ mn 54
Figure 26. North America Minimal Residual Disease Testing Market by Application: Multiple Myeloma (MM), 2021-2031, $ mn 55
Figure 27. North America Minimal Residual Disease Testing Market by Application: Acute Lymphoblastic Leukemia (ALL), 2021-2031, $ mn 56
Figure 28. North America Minimal Residual Disease Testing Market by Application: Chronic Lymphoblastic Leukemia (CLL), 2021-2031, $ mn 57
Figure 29. North America Minimal Residual Disease Testing Market by Application: Acute Myeloid Leukemia (AML), 2021-2031, $ mn 58
Figure 30. North America Minimal Residual Disease Testing Market by Application: Chronic Myeloid Leukemia (CML), 2021-2031, $ mn 59
Figure 31. North America Minimal Residual Disease Testing Market by Application: Hodgkin’s Lymphoma (HL), 2021-2031, $ mn 60
Figure 32. North America Minimal Residual Disease Testing Market by Application: Solid Tumor, 2021-2031, $ mn 61
Figure 33. North America Minimal Residual Disease Testing Market by Application: Other Applications, 2021-2031, $ mn 62
Figure 34. Breakdown of North America Minimal Residual Disease Testing Market by Technology, 2021-2031, % of Sales Revenue 64
Figure 35. North America Addressable Market Cap in 2022-2031 by Technology, Value ($ mn) and Share (%) 64
Figure 36. North America Minimal Residual Disease Testing Market by Technology: Flow Cytometry, 2021-2031, $ mn 65
Figure 37. North America Minimal Residual Disease Testing Market by Technology: Polymerase Chain Reaction (PCR), 2021-2031, $ mn 66
Figure 38. North America Minimal Residual Disease Testing Market by Technology: Next-Generation Sequencing (NGS), 2021-2031, $ mn 67
Figure 39. North America Minimal Residual Disease Testing Market by Technology: Other Technologies, 2021-2031, $ mn 68
Figure 40. Breakdown of North America Minimal Residual Disease Testing Market by End User, 2021-2031, % of Revenue 70
Figure 41. North America Addressable Market Cap in 2022-2031 by End User, Value ($ mn) and Share (%) 70
Figure 42. North America Minimal Residual Disease Testing Market by End User: Hospitals and Clinics, 2021-2031, $ mn 71
Figure 43. North America Minimal Residual Disease Testing Market by End User: Research Institutions, 2021-2031, $ mn 72
Figure 44. North America Minimal Residual Disease Testing Market by End User: Diagnostic Laboratories, 2021-2031, $ mn 73
Figure 45. North America Minimal Residual Disease Testing Market by End User: Other End Users, 2021-2031, $ mn 74
Figure 46. Breakdown of North America Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue 76
Figure 47. Contribution to North America 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 77
Figure 48. U.S. Minimal Residual Disease Testing Market, 2021-2031, $ mn 79
Figure 49. Canada Minimal Residual Disease Testing Market, 2021-2031, $ mn 81
Figure 50. Minimal Residual Disease Testing Market in Mexico, 2021-2031, $ mn 83
Figure 51. Growth Stage of North America Minimal Residual Disease Testing Industry over the Forecast Period 85
Research methodology is mainly referring to the practical how of any offered piece of research. More specifically, it’s all about how a researcher systematically designs a study in order to assure extremely valid as well as reliable results that ultimately address the targets and objectives of the research.
In any formal research including academic journal, article, dissertation and so on, there will be a special section on a research methodology that mainly describes what, by whom, how to gather as well as how to evaluate the data are provided.
This research methodology has been segmented into following types:
Primary Research:
It is said to be original information that the researchers collect for the crucial purposes of answering the research questions of readers with the help of surveys, observations and experiments.
Secondary Research:
The secondary research is the data that has already been collected by various other researchers in the form of government analysis or scientific studies.
Qualitative Research:
It is descriptive and subjective method irrespective of facts. Both observation and description are essential in this type of research methodology. Its main vision is to analyze knowledge, attitudes, behaviours as well as opinions of people related to the topic of any research. This method has been operated through grounded research, case study and actionable research.
Quantitative Research:
It contains several laboratory experiments, basic surveys, mathematical calculations, simulations and so on. The possible measurement, quantity or amount is considered to be a major factor in the quantitative research methodology.
Clients
